SCHEMBL4404615

SCHEMBL4404615

CCOc1cc(CC(=O)O)c(F)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.51
KDM4E B2RXH2 3/20 0.41
MAPT P10636 2/20 0.41
ABL1 P00519 1/20 0.41
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
RIN1 Q13671 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
TSHR P16473 3/20 0.40
ALDH1A1 P00352 2/20 0.38
RCE1 Q9Y256 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4407638 0.91 HSD17B10 (0.43) HSD17B10KDM4EMAPTABL1POLB
SCHEMBL4395632 0.88 HSD17B10 (0.51) HSD17B10KDM4EMAPTABL1POLB
SCHEMBL4395434 0.88 HSD17B10 (0.61) HSD17B10KDM4EMAPTABL1POLB
SCHEMBL4403037 0.82 MAPT (0.47) HSD17B10KDM4EMAPTABL1POLB
SCHEMBL4404809 0.81 PDE4A (0.42) KDM4EMAPTMEN1NPC1CYP3A4
SCHEMBL4410409 0.79 TSHR (0.45) HSD17B10KDM4EMAPTMEN1NPC1
SCHEMBL4405917 0.78 HSD17B10 (0.49) HSD17B10KDM4EMAPTABL1POLB
SCHEMBL4405835 0.77 TSHR (0.46) HSD17B10KDM4EMAPTMEN1NPC1
SCHEMBL4409356 0.77 KDM4E (0.43) HSD17B10KDM4EMAPTMEN1NPC1
SCHEMBL16071928 0.77 DPP4 (0.45) HSD17B10KDM4EMAPTMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 HSD17B10 2499/4885KDM4E 954/4885MAPT 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.